The Technical Analyst
Novo Nordisk A/S [NVO]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Novo Nordisk A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.34% $128.38
America/New_York / 9 mai 2024 @ 14:12
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 568 714 mill |
| EPS: | 2.88 |
| P/E: | 44.58 |
| Earnings Date: | Aug 07, 2024 |
| SharesOutstanding: | 4 429.77 mill |
| Avg Daily Volume: | 4.77 mill |
| RATING 2024-05-09 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 2.89x |
| Company: PE 44.58 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.10x |
| Company: PE 44.58 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$134.43 (4.71%) $6.05 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 125.83 - 130.90 ( +/- 1.97%) |
| ATR Model: 14 days |
Forecast:
15:50 - $128.33
Live Trading Signals (every 1 min)
Forecast
1: 14:20 - $128.33
Forecast 2: 15:10 - $128.57
Forecast 3: 15:50 - $128.33
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $128.38 (1.34% ) |
| Volume | 1.555 mill |
| Avg. Vol. | 4.77 mill |
| % of Avg. Vol | 32.62 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NVO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NVO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest Press Releases
2024-05-08 11:31:00 - Press Release
Novo Nordisk A/s: Trading In Novo Nordisk Shares By Board Members, Executives And Associated Persons
BagsvÆrd, denmark, 8 may 2024 — this company announcement discloses the data of the transaction(s) made in novo nordisk shares by the company's board members, executives and their associated persons in accordance with article 19 of regulation no. 596/2014 on market abuse.
2024-05-06 15:02:00 - Press Release
Trading In Novo Nordisk Shares By Board Members, Executives And Associated Persons
BagsvÆrd, denmark, 06 may 2024 – this company announcement discloses the data of the transaction(s) made in novo nordisk shares by the company's board members, executives and their associated persons in accordance with article 19 of regulation no. 596/2014 on market abuse.
2024-05-06 14:44:00 - Press Release
Novo Nordisk A/s - Share Repurchase Programme
BagsvÆrd, denmark, 06 may 2024 – the execution of novo nordisk a/s' overall share repurchase programme for 2024 of dkk 20 billion continues. as part of this, novo nordisk a/s has now initiated a new share repurchase programme of up to dkk 2.2 billion in accordance with article 5 of regulation no 596/2014 of the european parliament and council of 16 april 2014 (mar) and the commission delegated regulation (eu) 2016/1052 of 8 march 2016 (the "safe harbour rules”).
2024-05-06 14:40:00 - Press Release
Novo Nordisk A/s Purchases B Shares Worth Dkk 5,428 Million From Novo Holdings A/s Under The 2024 Share Repurchase Programme
BagsvÆrd, denmark, 06 may 2024 – today, novo nordisk a/s has entered into an agreement to purchase 6,311,250 b shares of dkk 0.10 at a value of dkk 5,427,801,225.00 million from novo holdings a/s. the transaction is part of novo nordisk a/s' 2024 share repurchase programme of up to a total of dkk 20 billion to be executed during a 12-month period beginning 6 february 2024. the transaction price is dkk 860.02 per share and has been calculated as the three-day volume weighted average market price from 2 may 2024 to 6 may 2024 in the open window following the announcement of novo nordisk a/s' quarterly financial results.
2024-05-03 13:48:00 - Press Release
Novo Nordisk A/s: Trading In Novo Nordisk Shares By Board Members, Executives And Associated Persons
BagsvÆrd, denmark, 3 may 2024 — this company announcement discloses the data of the transaction(s) made in novo nordisk shares by the company's board members, executives and their associated persons in accordance with article 19 of regulation no. 596/2014 on market abuse.
Latest News
2024-05-09 09:45:00 - The Motley Fool
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
Wegovy is a weight-loss drug that's proving it can do more than help people lose weight. Regulators recently approved it as a treatment for reducing cardiovascular risk.
2024-05-09 07:20:45 - Reuters
Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies
Metaphore Biotechnologies said on Thursday it would collaborate with Novo Nordisk to develop up to two therapies for obesity management.
2024-05-08 10:30:29 - Zacks Investment Research
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
2024-05-08 06:01:41 - Proactive Investors
Novo Nordisk eyeing upside on US weight loss drug rollout - analysts
Novo Nordisk (NYSE:NVO) could see consensus estimates boosted over the coming years as sales of its weight loss drugs pick up in the US, analysts say. Novo has 12 million patients on its GLP-1-based drugs, Citi analysts highlighted in a note, while the addressable population for the weight loss treatment approaches one billion.
2024-05-07 15:15:25 - CNBC
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
2024-05-07 14:04:24 - InvestorPlace
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
2024-05-07 11:33:29 - CNBC
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
2024-05-04 06:45:00 - The Motley Fool
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
The outlook for Pfizer's experimental obesity drug danuglipron is murky at best. Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.
2024-05-04 06:01:03 - Proactive Investors
Apple, Glencore, Sony, Novo Nordisk, Shell, Goldman Sach, GSK, Qualcomm, AMD, Starbucks, Amazon – Markets Defused
Markets Defused aims to present an easy-to-understand and straightforward recap of the week's most engaging stock market news Apple impressed Wall Street, Cook promises AI growth Sony stepped in with $26bn bid to buy Paramount Ozempic and Wegovy gave more record results at Novo Nordisk Goldman Sachs ready to boost banker bonuses in London Qualcomm optimistic about future smartphone sales AMD fell short of high expectations Starbucks revenues disappointed Amazon's beat expectations Apple financials impressed Wall Street, Cook promises AI growth Apple Inc (NASDAQ:AAPL, ETR:APC) investors welcomed the iPhone maker's latest earnings report on Thursday, buying up the shares following Thursday's report...
2024-05-03 14:39:42 - InvestorPlace
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
There are no true “under-the-radar stocks” in the traditional sense regarding companies with a market capitalization large enough to be viable candidates for a $1 trillion valuation in just six years. However, there are many overlooked gems whose immense potential fails to garner the attention it deserves from investors.